Bolt Biotherapeutics, Inc. — Q3 2022 Form 10-Q
Business context and period: Clinical-stage biopharmaceutical company developing cancer immunotherapies. This unaudited report covers the three and nine months ended September 30, 2022; comparisons are to the same 2021 periods. The company has no product-sales revenue. Its lead programs include BDC-1001, in a Phase 1/2 trial, and BDC-3042.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Collaboration revenue | $2.1 million | $0.8 million | $4.3 million | $0.8 million |
| Research and development expense | $19.0 million | $19.3 million | $56.3 million | $53.2 million |
| General and administrative expense | $5.5 million | $4.9 million | $17.3 million | $13.3 million |
| Net loss | $21.8 million | $23.4 million | $68.1 million | $71.4 million |
| Basic and diluted loss per share | $0.58 | $0.63 | $1.83 | $2.24 |
| Net cash used in operating activities | — | — | $58.6 million | $39.3 million |
Balance sheet at September 30, 2022: Cash and cash equivalents were $10.6 million; short- and long-term investments totaled $198.9 million, bringing cash, cash equivalents and marketable securities to approximately $209.6 million. Total assets were $245.5 million, total liabilities $57.1 million, and stockholders’ equity $188.4 million. Accumulated deficit was $275.1 million. The filing indicates no outstanding debt; lease liabilities totaled $23.2 million, including current and non-current amounts.
Cash flow and margins: Investing activities provided $41.4 million net, largely reflecting maturities of marketable securities, while financing activities provided $0.4 million. Cash, cash equivalents and restricted cash decreased $16.8 million over the nine months. The filing does not present a meaningful operating margin or gross margin measure for this development-stage business.
Material changes versus prior periods
- Q3 collaboration revenue increased $1.4 million year over year, primarily from progress on the Genmab and Innovent collaborations. Nine-month revenue rose $3.6 million.
- Q3 R&D expense declined $0.4 million, as lower manufacturing and personnel costs partly offset higher clinical-trial costs. Nine-month R&D expense increased $3.1 million, reflecting clinical and program development, personnel, facility, and professional-service costs, partly offset by lower manufacturing costs.
- Q3 G&A expense increased $0.5 million; nine-month G&A increased $4.0 million, principally from higher personnel costs and increased office- and travel-related expenses.
- Q3 net loss improved $1.6 million; the nine-month net loss improved $3.3 million. The 2021 comparison included a $6.1 million non-cash expense from remeasurement of a preferred-stock purchase-right liability; that item did not recur in 2022.
- Operating cash use increased $19.3 million year over year for the nine-month period. The company reported lower collaboration-related deferred revenue changes and higher cash use despite a lower net loss.
- Investments had $1.7 million of net unrealized losses at quarter-end, compared with $0.3 million at December 31, 2021; nine-month comprehensive loss was $69.5 million.
Outlook, risks and contingencies
- Management expects existing cash, cash equivalents and marketable securities to fund operations for at least 12 months following the filing’s issuance. Near-term spending priorities include key milestones for BDC-1001 and BDC-3042, clinical trials, manufacturing, R&D and employee costs. Management expects funding needs to rise as programs advance and may seek capital or partnering.
- The company continues to incur losses and negative operating cash flow and has no product revenue. Additional equity or debt financing, collaborations or licensing may be needed; financing could dilute shareholders or require concessions over product rights.
- Risks include clinical and regulatory uncertainty, dependence on single-source manufacturers and suppliers, and potential effects from COVID-19, inflation, labor shortages, recession risks and the Russia-Ukraine conflict. Management said COVID-19 had not materially adversely affected productivity or the business to date, but future impact remains uncertain.
- The company’s $75 million at-the-market equity program remained unused as of September 30, 2022; the broader shelf registration permits up to $250 million of securities offerings.
- Potential supply-agreement milestone payments were up to $2.0 million. Operating-lease minimum payments totaled $35.5 million before imputed interest, partly offset by $1.4 million of scheduled sublease income. No material pending legal claims were reported.
- Disclosure controls were deemed ineffective because of a material weakness in internal control over financial reporting, involving insufficient accounting personnel and inadequate formal accounting policies and controls. Remediation efforts were underway, but the weakness was not yet considered remediated.
Important facts for investors to verify
- Whether the stated 12-month liquidity runway remains adequate as trial, manufacturing and other program costs evolve.
- Clinical progress, timelines, safety and funding needs for BDC-1001 and BDC-3042, and the scope and timing of collaboration programs.
- Whether collaboration revenue and deferred-revenue balances translate into continued partner funding and services, particularly given the Toray program’s ongoing research-plan reevaluation.
- Progress in remediating the material weakness and the effectiveness of controls after sufficient testing.
- Potential future use of the ATM or other financing, dilution implications, supplier availability, and lease and milestone obligations.